Jan. 17, 2021, 12:06 a.m. EST

New Research Suggests Chronic Kidney Disease Market 2021, Rising Demand for New Techniques | Global Size, Share, Analysis and Forecast 2023

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jan 17, 2021 (Heraldkeepers) -- Global Chronic Kidney Disease Market - Overview

Market Research Future (MRFR) expects the Global Chronic Kidney Disease Market to exhibit a robust 5.2% CAGR over the forecast period from 2017 to 2023. The global chronic kidney disease market is mainly driven by the growing prevalence of hypertension, i.e. high blood pressure, and diabetes among the geriatric population around the world, which is growing at a rapid rate due to advances in medical technology, making longer lifetimes not just possible but normal.

GET PREMIUM SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/5744

Rising prevalence of hypertension is likely to be the major driving factor for the global chronic kidney disease market over the forecast period.

Rising prevalence of dietary factors enabling hypertension, including high consumption of heavy, red meats, heavy consumption of tobacco through cigarettes, and the increasingly sedentary lifestyles of the modern urban population have been responsible for the growing prevalence of hypertension in the developed world.

In developing regions as well, the prevalence of hypertension is growing due to the increasing adoption of Western dietary and lifestyle patterns. The growing consumption of fast food in the emerging Asia Pacific regions has led to growing prevalence of hypertension, which is a key cause of chronic kidney disease.

Competitive Dashboard:

Some of the key players profiled in the report are Beckman Coulter, F. Hoffmann-La Roche Ltd, Abbott, Siemens, Sysmex, ACON Laboratories, Inc., URIT Medical, 77 Elektronika, Randox Laboratories, Teva Pharmaceutical Industries Ltd., Amgen Inc., Nova Biomedical, ARKRAY, OPTI Medical, AstraZeneca Plc, Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Kissei Pharmaceutical Co. Ltd.

Market segmentation:

By diagnosis, the chronic kidney disease market is segmented into blood test, urine test, imaging test, and kidney biopsy.

By treatment, the global chronic kidney disease market has been segmented into drugs, dialysis, and kidney transplant. The drugs segment is further sub-segmented into ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.

By indication, the chronic kidney disease market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others.

By end-user, the global chronic kidney disease market has been segmented into hospitals and clinics, diagnostic centers, and others.

Global Chronic Kidney Disease Market - Regional Analysis

The global chronic kidney disease market is segmented into Americas, Europe, Asia Pacific, and the Middle East.

The Americas segment is likely to be the major regional market for chronic kidney disease treatment and diagnostic services over the forecast period due to the growing prevalence of kidney disease in the geriatric population in countries such as the U.S. and Canada.

The geriatric demographic is a significant portion of the population in these countries and is likely to comprise a major part of the region's healthcare expenditure over the forecast period. This is likely to drive the chronic kidney disease market in the U.S. and Canada, as the prevalence of chronic kidney disease is higher in the geriatric demographic than in the rest of the population.

Europe accounts for around 25% of the global chronic kidney disease market, with Asia Pacific following Europe closely. Europe is likely to remain an important market for chronic kidney disease research and product development due to the growing geriatric population in developed Western European countries such as Germany, France, Belgium, the Netherlands, and the UK and the high disposable income of consumers in these regions.

BROWSE PREMIUM RESEARCH REPORT DETAILS @ https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744

Industry Updates

A new study published in Lancet in February 2019 found that chronic kidney disease is deadlier in India than HIV/AIDS in terms of premature deaths of adults and took more than 135,000 lives in 2015. It is estimated to be the third deadliest disease over the next two decades, behind only heart disease and brain strokes. This illustrates the potential of the chronic kidney disease market in India, a key Southeast Asian market.

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.